These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

510 related articles for article (PubMed ID: 29476018)

  • 1. FDA Approval: Gemtuzumab Ozogamicin for the Treatment of Adults with Newly Diagnosed CD33-Positive Acute Myeloid Leukemia.
    Jen EY; Ko CW; Lee JE; Del Valle PL; Aydanian A; Jewell C; Norsworthy KJ; Przepiorka D; Nie L; Liu J; Sheth CM; Shapiro M; Farrell AT; Pazdur R
    Clin Cancer Res; 2018 Jul; 24(14):3242-3246. PubMed ID: 29476018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The EMA Review of Mylotarg (Gemtuzumab Ozogamicin) for the Treatment of Acute Myeloid Leukemia.
    Ali S; Dunmore HM; Karres D; Hay JL; Salmonsson T; Gisselbrecht C; Sarac SB; Bjerrum OW; Hovgaard D; Barbachano Y; Nagercoil N; Pignatti F
    Oncologist; 2019 May; 24(5):e171-e179. PubMed ID: 30898889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gemtuzumab ozogamicin for treatment of newly diagnosed CD33-positive acute myeloid leukemia.
    Gbadamosi M; Meshinchi S; Lamba JK
    Future Oncol; 2018 Dec; 14(30):3199-3213. PubMed ID: 30039981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FDA Approval Summary: Mylotarg for Treatment of Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia.
    Norsworthy KJ; Ko CW; Lee JE; Liu J; John CS; Przepiorka D; Farrell AT; Pazdur R
    Oncologist; 2018 Sep; 23(9):1103-1108. PubMed ID: 29650683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gemtuzumab ozogamicin for
    Lambert J; Pautas C; Terré C; Raffoux E; Turlure P; Caillot D; Legrand O; Thomas X; Gardin C; Gogat-Marchant K; Rubin SD; Benner RJ; Bousset P; Preudhomme C; Chevret S; Dombret H; Castaigne S
    Haematologica; 2019 Jan; 104(1):113-119. PubMed ID: 30076173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09-09): a randomised, open-label, multicentre, phase 3 trial.
    Döhner H; Weber D; Krzykalla J; Fiedler W; Kühn MWM; Schroeder T; Mayer K; Lübbert M; Wattad M; Götze K; Fransecky L; Koller E; Wulf G; Schleicher J; Ringhoffer M; Greil R; Hertenstein B; Krauter J; Martens UM; Nachbaur D; Samra MA; Machherndl-Spandl S; Basara N; Leis C; Schrade A; Kapp-Schwoerer S; Cocciardi S; Bullinger L; Thol F; Heuser M; Paschka P; Gaidzik VI; Saadati M; Benner A; Schlenk RF; Döhner K; Ganser A;
    Lancet Haematol; 2023 Jul; 10(7):e495-e509. PubMed ID: 37187198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gemtuzumab ozogamicin in acute myeloid leukemia: past, present and future.
    Gottardi M; Sperotto A; Ghelli Luserna Di Rorà A; Padella A; Cangini D; Giannini MB; Simonetti G; Martinelli G; Cerchione C
    Minerva Med; 2020 Oct; 111(5):395-410. PubMed ID: 32955828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia.
    Baron J; Wang ES
    Expert Rev Clin Pharmacol; 2018 Jun; 11(6):549-559. PubMed ID: 29787320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
    Bross PF; Beitz J; Chen G; Chen XH; Duffy E; Kieffer L; Roy S; Sridhara R; Rahman A; Williams G; Pazdur R
    Clin Cancer Res; 2001 Jun; 7(6):1490-6. PubMed ID: 11410481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The addition of gemtuzumab ozogamicin to chemotherapy in adult patients with acute myeloid leukemia.
    Kell J
    Expert Rev Anticancer Ther; 2016; 16(4):377-82. PubMed ID: 26942450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic/Pharmacodynamic Modeling to Support the Re-approval of Gemtuzumab Ozogamicin.
    Fostvedt LK; Hibma JE; Masters JC; Vandendries E; Ruiz-Garcia A
    Clin Pharmacol Ther; 2019 Nov; 106(5):1006-1017. PubMed ID: 31070776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of gemtuzumab ozogamicin for the treatment of de novo CD33-positive Acute Myeloid Leukaemia (AML) in Italy.
    Cairoli R; Furneri G; Di Virgilio R; Veggia B; Ferrara F
    BMC Health Serv Res; 2023 Jan; 23(1):36. PubMed ID: 36642712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Benefits and Safety of Gemtuzumab Ozogamicin in Treating Acute Myeloid Leukemia in Various Subgroups: An Updated Systematic Review, Meta-Analysis, and Network Meta-Analysis.
    Xu Q; He S; Yu L
    Front Immunol; 2021; 12():683595. PubMed ID: 34484181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population Pharmacokinetic Modeling of Gemtuzumab Ozogamicin in Adult Patients with Acute Myeloid Leukemia.
    Hibma J; Knight B
    Clin Pharmacokinet; 2019 Mar; 58(3):335-347. PubMed ID: 30062662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gemtuzumab Ozogamicin Combined With Intensive Chemotherapy in Patients With Acute Myeloid Leukemia Relapsing After Allogenic Stem Cell Transplantation.
    Genthon A; Brissot E; Malard F; van de Wyngaert Z; Bonnin A; Banet A; Marjanovic Z; Ikhlef S; Lapusan S; Sestili S; Corre E; Paviglianiti A; Adaeva R; 'Hammedi-Bouzina FM; Labopin M; Dulery R; Mohty M; Legrand O
    Clin Lymphoma Myeloma Leuk; 2020 Dec; 20(12):791-796. PubMed ID: 32741743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rationale and design of the 2 by 2 factorial design GnG-trial: a randomized phase-III study to compare two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and to compare double-blinded intensive postremission therapy with or without glasdegib in older patients with newly diagnosed AML.
    Jaramillo S; Krisam J; Le Cornet L; Kratzmann M; Baumann L; Sauer T; Crysandt M; Rank A; Behringer D; Teichmann L; Görner M; Trappe RU; Röllig C; Krause S; Hanoun M; Hopfer O; Held G; Buske S; Fransecky L; Kayser S; Schliemann C; Schaefer-Eckart K; Al-Fareh Y; Schubert J; Geer T; Kaufmann M; Brecht A; Niemann D; Kieser M; Bornhäuser M; Platzbecker U; Serve H; Baldus CD; Müller-Tidow C; Schlenk RF
    Trials; 2021 Nov; 22(1):765. PubMed ID: 34732236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trials with gemtuzumab ozogamicin (Mylotarg) combined with chemotherapy regimens in acute myeloid leukemia.
    Stadtmauer EA
    Clin Lymphoma; 2002 Mar; 2 Suppl 1():S24-8. PubMed ID: 11970767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemia.
    Chevallier P; Delaunay J; Turlure P; Pigneux A; Hunault M; Garand R; Guillaume T; Avet-Loiseau H; Dmytruk N; Girault S; Milpied N; Ifrah N; Mohty M; Harousseau JL
    J Clin Oncol; 2008 Nov; 26(32):5192-7. PubMed ID: 18854573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gemtuzumab ozogamicin for acute myeloid leukemia.
    Appelbaum FR; Bernstein ID
    Blood; 2017 Nov; 130(22):2373-2376. PubMed ID: 29021230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin: a randomized phase II trial in elderly patients.
    Brunnberg U; Mohr M; Noppeney R; Dürk HA; Sauerland MC; Müller-Tidow C; Krug U; Koschmieder S; Kessler T; Mesters RM; Schulz C; Kosch M; Büchner T; Ehninger G; Dührsen U; Serve H; Berdel WE
    Ann Oncol; 2012 Apr; 23(4):990-6. PubMed ID: 21810729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.